Genotype is associated with left ventricular reverse remodelling and early events in recent-onset dilated

Milos Kubanek1,2, Jana Binova1,3, Lenka Piherova4

  • 1Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

ESC Heart Failure
|August 12, 2024
PubMed
Abstract

Insights

Genetic variants in recent-onset dilated cardiomyopathy (RODCM) predict outcomes. Non-titin variants indicate higher risk for heart failure and arrhythmias, aiding early risk stratification.

Area of Science:

  • Cardiology
  • Genetics
  • Genomics

Background:

  • Recent-onset dilated cardiomyopathy (RODCM) presents with varied causes and outcomes.
  • Genotype-phenotype correlations in RODCM are not well-established.
  • Understanding genetic factors is crucial for predicting RODCM progression.

Purpose of the Study:

  • To correlate specific RODCM genotypes with left ventricular reverse remodelling (LVRR).
  • To assess the relationship between genotypes and clinical outcomes in RODCM patients.
  • To identify genetic predictors for adverse events in RODCM.

Main Methods:

  • Prospective study of 386 Czech RODCM patients with symptom duration ≤6 months.
  • Whole-exome sequencing (WES) to identify pathogenic/likely pathogenic variants (class 4-5) in 72 cardiomyopathy-related genes.
  • Correlation of genetic findings with primary (death, transplant, VAD) and secondary (ventricular arrhythmia) outcomes, and LVRR over a median 41-month follow-up.

Main Results:

  • Pathogenic variants (class 4-5) were found in 32% of patients (18% titin-truncating variants [TTNtv], 14% non-titin variants [non-TTN]).
  • Class 4-5 non-TTN variants, unlike TTNtv, predicted lower LVRR probability and were independent predictors of primary and secondary outcomes.
  • Variants in nuclear envelope genes predicted adverse outcomes and arrhythmias; cytoskeleton gene variants increased arrhythmia risk. Negative genetic testing was protective.

Conclusions:

  • RODCM patients with class 4-5 non-TTN variants face increased risk of heart failure progression and life-threatening ventricular arrhythmias.
  • Genotyping offers a valuable tool for early risk stratification in RODCM patients at baseline.
  • Identifying specific genetic markers can guide personalized management strategies for RODCM.